Judi van Diessen

The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)

Judi van Diessen, Dirk De Ruysscher, Jan‐Jakob Sonke et al. · Radiotherapy and Oncology · 2018 · 76 citations · Full text

Pet-boost Trial, Medicine, Metronomic Therapy +9

Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas

J.F. Van den Hoek, Karen Bloemendal, Lilly-Ann van der Velden et al. · Cancers · 2016 · 73 citations · Full text

Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab

Iris Walraven, Michel M. van den Heuvel, Judi van Diessen et al. · Radiotherapy and Oncology · 2016 · 68 citations · Full text

Long-term Follow-up, Radiation Therapy, Medicine +6

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

Rosemarie de Haan, Michel M. van den Heuvel, Judi van Diessen et al. · Clinical Cancer Research · 2020 · 54 citations · Full text

Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy

Barbara Stam, Erik van der Bijl, Judi van Diessen et al. · Radiotherapy and Oncology · 2017 · 45 citations

Heart Failure, Radiation Therapy, Overall Survival +9